Neena Bitritto-Garg
Stock Analyst at Deutsche Bank
(2.76)
# 2,058
Out of 5,090 analysts
75
Total ratings
43.86%
Success rate
7.64%
Average return
Main Sectors:
Stocks Rated by Neena Bitritto-Garg
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ACAD ACADIA Pharmaceuticals | Maintains: Hold | $22 → $20 | $27.44 | -27.11% | 17 | May 8, 2025 | |
| ROIV Roivant Sciences | Maintains: Buy | $14 → $15 | $20.97 | -28.47% | 5 | Apr 3, 2024 | |
| AMLX Amylyx Pharmaceuticals | Maintains: Buy | $36 → $8 | $14.20 | -43.66% | 7 | Mar 11, 2024 | |
| IMVT Immunovant | Initiates: Buy | $50 | $22.84 | +118.91% | 1 | Dec 12, 2023 | |
| NBIX Neurocrine Biosciences | Initiates: Buy | $136 | $155.51 | -12.55% | 7 | Dec 12, 2023 | |
| CMPS COMPASS Pathways | Initiates: Buy | $16 | $5.82 | +174.91% | 4 | Dec 12, 2023 | |
| PRTA Prothena Corporation | Initiates: Buy | $62 | $11.07 | +460.07% | 8 | Dec 12, 2023 | |
| ALEC Alector | Initiates: Buy | $12 | $1.22 | +883.61% | 6 | Dec 12, 2023 | |
| SRPT Sarepta Therapeutics | Initiates: Buy | $109 | $22.26 | +389.67% | 3 | Dec 12, 2023 | |
| ABOS Acumen Pharmaceuticals | Initiates: Buy | $8 | $1.86 | +330.11% | 1 | Dec 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $20 → $10 | $4.32 | +131.48% | 4 | Jan 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $140 → $100 | $9.21 | +985.78% | 3 | Nov 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | $6 | $24.34 | -75.35% | 5 | Aug 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $21 | $3.89 | +439.85% | 1 | Apr 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $23 | $204.00 | -88.73% | 1 | Jul 11, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $36 | $44.41 | -18.94% | 2 | Jul 11, 2017 |
ACADIA Pharmaceuticals
May 8, 2025
Maintains: Hold
Price Target: $22 → $20
Current: $27.44
Upside: -27.11%
Roivant Sciences
Apr 3, 2024
Maintains: Buy
Price Target: $14 → $15
Current: $20.97
Upside: -28.47%
Amylyx Pharmaceuticals
Mar 11, 2024
Maintains: Buy
Price Target: $36 → $8
Current: $14.20
Upside: -43.66%
Immunovant
Dec 12, 2023
Initiates: Buy
Price Target: $50
Current: $22.84
Upside: +118.91%
Neurocrine Biosciences
Dec 12, 2023
Initiates: Buy
Price Target: $136
Current: $155.51
Upside: -12.55%
COMPASS Pathways
Dec 12, 2023
Initiates: Buy
Price Target: $16
Current: $5.82
Upside: +174.91%
Prothena Corporation
Dec 12, 2023
Initiates: Buy
Price Target: $62
Current: $11.07
Upside: +460.07%
Alector
Dec 12, 2023
Initiates: Buy
Price Target: $12
Current: $1.22
Upside: +883.61%
Sarepta Therapeutics
Dec 12, 2023
Initiates: Buy
Price Target: $109
Current: $22.26
Upside: +389.67%
Acumen Pharmaceuticals
Dec 12, 2023
Initiates: Buy
Price Target: $8
Current: $1.86
Upside: +330.11%
Jan 9, 2023
Maintains: Buy
Price Target: $20 → $10
Current: $4.32
Upside: +131.48%
Nov 11, 2022
Maintains: Buy
Price Target: $140 → $100
Current: $9.21
Upside: +985.78%
Aug 2, 2022
Downgrades: Sell
Price Target: $6
Current: $24.34
Upside: -75.35%
Apr 4, 2022
Initiates: Buy
Price Target: $21
Current: $3.89
Upside: +439.85%
Jul 11, 2017
Initiates: Outperform
Price Target: $23
Current: $204.00
Upside: -88.73%
Jul 11, 2017
Initiates: Outperform
Price Target: $36
Current: $44.41
Upside: -18.94%